Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GenVec, Inc.
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.
Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.
French VC firm Truffle Capital has raised €250 million ($278m) for its new BioMedTech fund. The capital will be used to create 12 new medtech companies.